Invida Announces Joint Venture with Indonesian Pharmaceutical Manufacturer

Partnership with P.T. MUGI Laboratories to Support South-East Asian Capabilities

Singapore – May 20, 2010 – Invida Group, the leading specialty biopharmaceutical company focused

on the commercialization of healthcare products throughout Asia Pacific, today announced that it has

completed a joint venture agreement with the Indonesian pharmaceutical manufacturer MUGI. The

acquisition of MUGI will allow Invida to leverage its full suite of capabilities throughout Indonesia and

open up the Indonesian market for Invida’s partners, as well as allowing Invida to offer a range of

partnering options unique on this scale in Indonesia.

Local regulations require foreign pharmaceutical entities to operate a local manufacturing facility in

order to register their products in the country. With this agreement, Invida will be able to expand its

capabilities in Indonesia to include the importation of raw materials and auxiliaries, possession of any

and all regulatory licenses for pharmaceutical products, arrangement of toll manufacturing support

where needed, in addition to continuing to provide its marketing expertise throughout the archipelago.

and an important growth opportunity for Invida. We continue to work on positioning ourselves as a

preferred partner offering full market access, regulatory and commercialization capabilities. Our

current sales force in this market has given us a foothold that is unmatched by our international peers,

and the ability to offer Invida’s full range of capabilities in Indonesia will be a tremendous benefit to our

partners. This will ensure that our partners’ brands can rapidly reach the market and in turn, be

accessible to doctors and patients throughout Indonesia. With the acquisition of MUGI, Invida also

further cements its role as a single point of entry for those companies looking for a strategic partner to

access Asia Pacific markets.”

MUGI’s manufacturing plant currently produces a variety of pharmaceutical products and has offerings

in dermatology, consumer health and primary care, which are well aligned with Invida’s strategy and

current capabilities. Under the terms of the agreement, Invida has acquired a 70% stake in the

company with MUGI’s owners retaining the remaining stake through its investment vehicle. Through

Invida’s leadership, the plant will undergo a major upgrade to ensure that it is able to meet all

regulatory compliance requirements and the demands of its international partners.

The agreement is mutually beneficial to both parties and enables MUGI to grow its business and

leverage Invida’s wide resources and sales force throughout Indonesia. The agreement will allow

Invida’s partners to gain fully authorized, unfettered access to the Indonesian pharmaceutical market

and to rely on a regional partner who will uphold international standards in manufacturing, licensing,

and marketing practices

About Invida Group Pte Ltd

Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical

products of superior quality - the result of which will allow all our stakeholders to prosper. We do

this through our proven brand marketing and sales know-how, strong expertise across a number

of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive

functional capabilities provide rapid market access delivered by our passionate team of

professionals.

With more than 4,000 employees in 13 markets in Asia Pacific, Invida operates across the

commercial value chain from regulatory approval and product launch to lifecycle management.

We manage a portfolio of proprietary healthcare brands as well as licensed products from small

biotech firms and large multinational companies. Partnering is a critical component of Invida’s

business model. We collaborate closely with our partners in developing effective strategies and

put our extensive experience behind maximizing the potential of the assets entrusted to us.